SAB Biotherapeutics

SAB Biotherapeutics completes first phase at production pharm

SAB Biotherapeutics has completed the initial phase of an 80-acre production pharm near Canton.

6 years ago

Bioscience leader to share insight at Zeal Ignite event

The chief science officer for promising biotech startup SAB Biotherapeutics will update work at his company and give an overview of the bioscience landscape in South Dakota at an event Oct. 9 from the Zeal Center for Entrepreneurship.

6 years ago

Denny Sanford invests additional $10M in SAB Biotherapeutics

SAB Biotherapeutics Inc., a Sioux Falls-based clinical stage biopharmaceutical development company, has received a $10 million investment from T. Denny Sanford.

6 years ago

SAB immunotherapy neutralizes Ebola in animal study

Sioux Falls-based SAB Biotherapeutics used its anti-Ebola immunotherapy to provide 100 percent protection against a lethal dose of the disease in a recent animal study.

6 years ago

USD Discovery District: The road ahead for biotech companies, development

“There’s absolutely a rising tide in South Dakota.” We look at the road ahead for bioscience and the USD Discovery District following last week’s big announcement.

6 years ago
Discovery District

Biopharmaceutical companies to locate at USD Discovery District

SAB Biotherapeutics and Alumend are the first companies to announce plans to locate at the USD Discovery District.

6 years ago

One Health: The future of biotech and a fit for South Dakota

An emerging initiative called One Health is bringing together those who work in human medicine, veterinary medicine and environmental science, with big implications for the biotech industry in South Dakota.

6 years ago

One Health: Biotechnology sector ready to act

The emerging concept of “One Health” uses the interconnectedness of all living things to address disease outbreaks. Sioux Falls CEO Eddie Sullivan weighs in on why his sector — and company — are positioned to help.

6 years ago

SAB: First MERS treatment appears safe in clinical trial

The anti-MERS immunotherapy developed by Sioux Falls biotech company SAB Biotherapeutics Inc. appears safe in phase 1 clinical trials, the company announced.

6 years ago

SAB Biotherapeutics announces successful human trial

There’s a big development to announce for SAB Biotherapeutics, which has spent the past year testing its technology in a patient.

6 years ago

News Tip

Have a business news item to share with us?

Scroll to top